The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developing a clinic-bound therapeutic. Join Dr. Igor Oruetexebarria, senior scientist at Kuopio Center for Gene and Cell Therapy, as he walks through some of the current challenges in the field of gene therapy AAV development, and explains how the nanoDSF and DLS capabilities of the Prometheus Panta have improved the outcomes for his vector candidates.
Most recent content
17:08Assess the impact of conjugation with multi-parameter stability characterization
Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.
19:07How stability prediction experiments give you confidence in your ADCs
For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.
20:31The power of Monolith X for Characterizing GPCRs: Accelerating Binding Affinity Measurements
To understand signaling pathways, Spectral Shift technology allows for accurate bindings affinity measurements of membrane proteins like GPCRs in close to native conditions.
14:18Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap
11:48Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors
MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study
38:20Conversation: How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation
Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps
19:16How to mitigate risk during ADC development with multi-parameter stability characterization
To assess the developability properties of antibody-drug conjugates (ADCs) learn about multi-parameter characterization of thermal and colloidal stability with Prometheus Panta using nanoDSF and DLS
38:31nanoDSF for biologics: How to interpret thermal unfolding profiles for your different applications
Thermal stability screening is a common approach used to study the developability of a wide range of protein-based therapeutics. Among the different technologies available to perform thermal stability
24:28Thermal stability measurements for biologics developability profiling
Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.
22:23Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
8:38Explore Prometheus Panta – Frequently asked questions about stability profiling experiments
In this video, Nathan Wallace, Application Specialist at NanoTemper, addresses common questions about experimental design for developability profiling and the operation of Prometheus Panta.
20:19Explore Prometheus Panta – Biologics developability assessment with four integrated technologies
Developability assessment is a critical part of the evaluation and selection of candidates for further optimization and development for biologics researchers. This work entails collecting, ranking, an
16:42How to keep your degrader pipeline moving forward with Dianthus
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
21:31How biologics teams approach developability screening of their candidates with combinatorial stability characterization
Full developability profiles de-risk the selection process for biologics candidates during early development workflows. There are many critical quality attributes to evaluate when it comes to developa
17:33How to use light scattering techniques to predict your biologic's self-association behavior at high concentrations
Developability work requires the assessment of multiple critical quality attributes (CQAs) of your biologics. Many of these CQAs are measured or monitored using low-volume, low-concentration samples.
13:12How biologics teams use Dynamic Light Scattering to identify leading candidates
Watch this 15 min video to learn how groups in early biologics development and formulation use Dynamic Light Scattering (DLS) to make informed decisions that de-risk downstream biologics development.
37:25Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
21:48How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods
Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
25:16Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
28:21Join Dr. Brittney Mills as she explains what criteria AbbVie’s preformulation department screens for in their antibody candidates.